{"id":55896,"date":"2023-04-17T17:03:20","date_gmt":"2023-04-17T15:03:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/"},"modified":"2023-04-17T17:03:20","modified_gmt":"2023-04-17T15:03:20","slug":"former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/","title":{"rendered":"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions"},"content":{"rendered":"
\n

BOSTON & NEW YORK–(BUSINESS WIRE)–#Accountability<\/a>–Brainwave Science acknowledges receipt of a letter of apology from Dr. Thierry Maison regarding his role in an attempted scheme to infringe upon Brainwave\u2019s intellectual property.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe attempted infringement, which involved a legacy version of our software, was contained by way of a preliminary injunction from the United States District Court. Maison was a named a co-defendant in the Theft of Trade Secrets claim brought by Brainwave in the New York Federal District Court (Brainwave Science, Inc. v. Arshee et. al. 21-cv-4402 (BMC) (E.D.N.Y<\/i>.). In March 2023, Brainwave was awarded Permanent Injunctions, as well as nominal and punitive damages awards aggregating in excess of $750,000.00, against Maison and his co-defendants.<\/p>\n

\nDr. Maison\u2019s letter filed with the Federal District Court expresses sincere regret for any harm caused and acknowledges his responsibility for the incident. We appreciate Dr. Maison’s willingness to take accountability for his actions and take steps towards making amends. As a company, we value transparency, honesty, and accountability, and we believe that this apology demonstrates those values. We want to assure our customers, stakeholders, and the public that we take all incidents seriously and will always strive to resolve such issues in a fair and timely manner.<\/p>\n

\n___________________<\/b><\/p>\n

\nBrainwave Science, Inc. is a leading developer of neuroscience-based technology solutions for National Security, Homeland Security, law enforcement, and other applications. The company’s flagship product, iCognative\u00ae, uses proprietary P300 science technology to identify the presence or absence of specific information in a person’s brain, providing accurate and reliable intelligence to help solve crimes, prevent terrorist attacks and organized crime. Potential Healthcare and other applications for the technology are presently being developed and explored within sponsored research studies by preeminent international and United States research institutions. Information about our security and investigations applications can be found at https:\/\/brainwavescience.com<\/a>. For more information about our healthcare and preventative medicine applications visit our affiliate website at www.Basilhealth.ai<\/a><\/i><\/p>\n

\nThis matter was investigated by Brainwave Science\u2019s Senior Investigator, Raymond Tahir (Former Agent, Federal Bureau of Investigation). Brainwave Science, Inc. was represented in its Federal Theft of Trade Secrets claims by Paul Forrest Tomkins, Esq.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nPaul Tomkins, In House Counsel: ptomkins@brainwavescience.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON & NEW YORK–(BUSINESS WIRE)–#Accountability–Brainwave Science acknowledges receipt of a letter of apology from Dr. Thierry Maison regarding his role in an attempted scheme to infringe upon Brainwave\u2019s intellectual property. The attempted infringement, which involved a legacy version of our software, was contained by way of a preliminary injunction from the United States District Court. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55896","6":"format-standard","7":"category-industry"},"yoast_head":"\nFormer Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON & NEW YORK–(BUSINESS WIRE)–#Accountability–Brainwave Science acknowledges receipt of a letter of apology from Dr. Thierry Maison regarding his role in an attempted scheme to infringe upon Brainwave\u2019s intellectual property. The attempted infringement, which involved a legacy version of our software, was contained by way of a preliminary injunction from the United States District Court. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T15:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230417005184\/en\/1764442\/21\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions\",\"datePublished\":\"2023-04-17T15:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/\"},\"wordCount\":398,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005184\\\/en\\\/1764442\\\/21\\\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/\",\"name\":\"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005184\\\/en\\\/1764442\\\/21\\\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg\",\"datePublished\":\"2023-04-17T15:03:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005184\\\/en\\\/1764442\\\/21\\\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005184\\\/en\\\/1764442\\\/21\\\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/","og_locale":"en_US","og_type":"article","og_title":"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions - Pharma Trend","og_description":"BOSTON & NEW YORK–(BUSINESS WIRE)–#Accountability–Brainwave Science acknowledges receipt of a letter of apology from Dr. Thierry Maison regarding his role in an attempted scheme to infringe upon Brainwave\u2019s intellectual property. The attempted infringement, which involved a legacy version of our software, was contained by way of a preliminary injunction from the United States District Court. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-17T15:03:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230417005184\/en\/1764442\/21\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions","datePublished":"2023-04-17T15:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/"},"wordCount":398,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230417005184\/en\/1764442\/21\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/","url":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/","name":"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230417005184\/en\/1764442\/21\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg","datePublished":"2023-04-17T15:03:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230417005184\/en\/1764442\/21\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230417005184\/en\/1764442\/21\/Maison_Final_Release_-_Asset_%231_-_Apology_Letter.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/former-chief-technology-officer-issues-letter-of-apology-to-brainwave-science-for-unlawful-and-dishonest-actions-in-wake-of-federal-defense-of-trade-secret-injuncti\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Former Chief Technology Officer Issues Letter of Apology to Brainwave Science for \u201cUnlawful\u201d and \u201cDishonest\u201d Actions in Wake of Federal Defense of Trade Secret Injunctions"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55896"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55896\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}